Exact Sciences Corp reports results for the quarter ended June 30 - Earnings Summary

• Exact Sciences Corp EXAS.OQ reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -9 cents. The mean expectation of twenty five analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -62 cents to -1 cents per share.

• Revenue rose 16% to $811.09 million from a year ago; analysts expected $774.67 million.

• Exact Sciences Corp shares had fallen by 10.9% this quarter and lost 15.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 24.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Exact Sciences Corp is $68.06, about 30.4% above its last closing price of $47.36

This summary was machine generated from LSEG data August 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)